Neurizon Therapeutics (ASX:NUZ) said Michael Thurn has resigned as managing director and chief executive officer, stepping down from his executive responsibilities from March 16, with his contractual notice period concluding in July 2026, according to a Monday Australian bourse filing.

Thurn will continue to serve as a non-executive director until the completion of his notice period, the filing added.

The company said Sergio Duchini will assume the role of interim executive chair until a suitable chief executive is appointed, while a global search for a new CEO is underway with the assistance of executive search firm Coulter Partners.

The company's shares fell 13% in recent Monday trade.